

**Real-time RT-PCR for Venezuelan equine encephalitis complex, Madariaga and Eastern equine encephalitis viruses: application in human and mosquito public health surveillance in Panama**

Jean-Paul Carrera<sup>1,2,3,4#</sup>, Dimelza Araúz<sup>3</sup>, Alejandra Rojas<sup>5</sup>, Fátima Cardozo<sup>5</sup>, Victoria Stittleburg<sup>6</sup>, Ingra Morales Claro<sup>7,9</sup>, Josefrancisco Galue<sup>3,4</sup>, Carlos Lezcano-Coba<sup>3,4</sup>, Filipe Romero Rebello Moreira<sup>8,9</sup>, Luis Felipe-Rivera<sup>3,4</sup>, Maria Chen-Germán<sup>3</sup>, Brechla Moreno<sup>3</sup>, Zeuz Capitan-Barrios<sup>3,4,10</sup>, Sandra López-Vérges<sup>3</sup>, Juan Miguel Pascale<sup>11</sup>, Ester C. Sabino<sup>7</sup>, Anayansi Valderrama<sup>4,12</sup>, Kathryn A. Hanley<sup>13</sup>, Christl A. Donnelly<sup>2,9,14</sup>, Nikos Vasilakis<sup>+15, 16,17,18,19,20</sup>, Nuno R. Faria<sup>+1,7,9</sup>, Jesse J. Waggoner<sup>+6,21,#</sup>

1. Department of Biology, University of Oxford, Oxford, United Kingdom

2. Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

3. Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama

4. Viral Emerging Disease Dynamics group, Gorgas Memorial Institute of Health Studies, Panama City, Panama

5. Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud, Departamento de Producción, Paraguay

6. Emory University, Department of Medicine, Division of Infectious Diseases, Atlanta, Georgia, USA

7. Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
8. Departamento de Genética, Universidade Federal do Rio de Janeiro, Brazil
9. MRC Centre for Global Infectious Disease Analysis (MRC-GIDA), Department of Infectious Disease Epidemiology, Imperial College London, London United Kingdom
10. Departamento de Microbiología y Parasitología, Facultad de Ciencias Naturales, Exactas y Tecnología, Universidad de Panamá, Ciudad de Panamá, Panamá
11. Clinical of Tropical Diseases and Research Unit, Gorgas Memorial Institute of Health Studies, Panama City, Panama
12. Department of Medical Entomology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
13. Department of Biology, New Mexico State University, Las Cruces, New Mexico, USA
14. Department of Statistics, University of Oxford, Oxford, United Kingdom
15. Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA
16. Department of Preventive Medicine and Population Health, The University of Texas Medical Branch, Galveston, Texas, USA.
17. Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston, Texas, USA.
18. Center for Vector-Borne and Zoonotic Diseases, The University of Texas Medical Branch, Galveston, Texas, USA.
19. Center for Tropical Diseases, The University of Texas Medical Branch, Galveston, Texas, USA.

20. Institute for Human Infection and Immunity, The University of Texas Medical Branch,  
Galveston, Texas, USA.

21. Rollins School of Public Health, Department of Global Health, Atlanta, Georgia, USA

Running Head: **rRT-PCR for VEEV complex, MADV, and EEEV**

#Address correspondence to: Jean-Paul Carrera, Peter Medawar Building for Pathogen Research,  
Oxford, UK, OX1 3SY. Email: [jean.carrera@biology.ox.ac.uk](mailto:jean.carrera@biology.ox.ac.uk); [jpcarrera@gorgas.gob.pa](mailto:jpcarrera@gorgas.gob.pa); Nuno  
R. Faria, Department of Infectious Disease Epidemiology, Imperial College London, London  
UK, Email: [nfaria@ic.ac.uk](mailto:nfaria@ic.ac.uk); or Jesse J. Waggoner, 1760 Haygood Drive NE, Room E-169, Bay  
E-1, Atlanta, GA, USA, 30322. Email: [jjwaggo@emory.edu](mailto:jjwaggo@emory.edu); Telephone: +1 (404) 712-2360.

+joint senior authors

Word Count: Abstract, 192; Manuscript, 2940

Inserts: Tables 4, Figure 4

## **Abstract**

Eastern equine encephalitis virus (EEEV), Madariaga virus (MADV), and Venezuelan equine  
encephalitis virus complex (VEEV) are New World alphaviruses transmitted by mosquitoes.  
They cause febrile and sometimes severe neurological disease in human and equine hosts.  
Detecting them during the acute phase is hindered by nonspecific symptoms and limited  
diagnostic tools. We designed and clinically assessed reverse transcription polymerase chain

reaction assays (rRT-PCRs) for VEEV complex, MADV, and EEEV using whole-genome sequences. Validation involved 15 retrospective serum samples from 2015-2017 outbreaks, 150 mosquito pools from 2015, and 118 prospective samples from 2021-2022 surveillance in Panama. The rRT-PCRs detected VEEV complex RNA in 10 samples (66.7%) from outbreaks, with one having both VEEV complex and MADV RNAs. VEEV complex RNA was found in 5 suspected dengue cases from disease surveillance. The rRT-PCR assays identified VEEV complex RNA in 3 *Culex (Melanoconion) vomerifer* pools, leading to VEEV isolates in 2. Phylogenetic analysis revealed the VEEV ID subtype in positive samples. Notably, 11.9% of dengue-like disease patients showed VEEV infections. Together, our rRT-PCR validation in human and mosquito samples suggests this method can be incorporated into mosquito and human encephalitic alphavirus surveillance programs in endemic regions.

**Keywords:** Venezuelan equine encephalitis, Madariaga virus, Eastern equine encephalitis virus, alphavirus, rRT-PCR.

## **Introduction**

New World alphaviruses (*Togaviridae*, genus *Alphavirus*) are a diverse group of mosquito-borne viruses that can cause severe disease in humans, including the Venezuelan equine encephalitis virus complex (VEEV complex), Madariaga virus (MADV), and eastern equine encephalitis virus (1, 2). These persist in sylvatic-enzootic cycles throughout the Americas and are transmitted to humans by *Aedes* spp., *Psorophora* spp. and *Culex* spp. mosquitoes (2, 3).

Serologic and molecular evidence points to widespread VEEV complex infections in tropical Central and South America, indicating potential commonality yet significant underdiagnosis (2) . At least 14 different viral subtypes within the VEEV complex, are identified to date (2), some associated with large equine and human outbreaks (VEEV subtypes IAB and IC) (1, 2). While most infections in humans are asymptomatic or subclinical, patients may develop acute febrile illness with headache, myalgias, arthralgias, nausea, and vomiting (4, 5). Cases can progress to encephalitis and result in long-term neurological effects (5, 6).

MADV, once considered a variant of EEEV, is an emerging virus that was first associated with large outbreaks in 2010 in the Darién province of Panamá (5), where VEEV subtype ID has also been detected (7). MADV was primarily linked to equine disease, with a few human cases in Trinidad and Tobago and Brazil before the Panama outbreak (8, 9). This contrasts with North American EEEV, associated with severe and fatal human cases (3). MADV detection methods are limited, and its prevalence outside Darién province is not well understood (10). MADV geographic expansion to Northeast Brazil and Haiti highlights its potential for new areas (11, 12).

Accurate detection of VEEV complex, MADV, and EEEV during the acute phase is hindered by non-specific clinical signs and limited diagnostic tools. Antigen-based methods are unavailable, and serology requires paired samples to confirm diagnosis (1, 5). Current molecular tests lack optimal performance characteristics necessary for routine testing (13–19), and assay design is challenged by VEEV complex genetic variability (2). VEEV complex and MADV are often misdiagnosed as dengue virus due to similar symptoms during the acute phase (2). Common

molecular tests involve pan-alphavirus primers amplifying a 400-500 nucleotide genome region, followed by sequencing or nested PCR for identification (5, 13, 14, 16, 18–20). These methods are labor-intensive and prone to contamination. Pan-alphavirus primers and conventional RT-PCR chemistry may be less sensitive than real-time RT-PCR (rRT-PCR), with few reported rRT-PCR methods differentiating VEEV complex and MADV (21).

The study aimed to design rRT-PCRs for VEEV complex and MADV, with a secondary goal of developing a duplex MADV/EEEV rRT-PCR. These assays were evaluated using clinical samples from a Panama alphavirus outbreak and disease surveillance. Additionally, viral species, subtype, and genotype characterization were done using metagenomic sequencing on rRT-PCR positive samples from humans and mosquitoes collected during 2015 and 2022 outbreaks in Panama.

## **Materials and Methods**

### **Ethics statement**

The use of human samples used for protocol validation was approved by the Panamanian Ministry of Health (protocol number 2077), Gorgas's Institutional Review Board (IRB) (protocol: 335/CBI/ICGES/21), Emory University IRB (IRB00097089), and the Ethics Committee of the Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (P06/2017). Prospective disease surveillance was approved by the Gorgas's IRB (protocol:073/CBI/ICGES/21).

## **Data availability**

All the data used for human and mosquito validation are contained within the manuscript. Accession numbers for the newly generated genomes are XXXX. Accession numbers and strain information of sequences used for primer design are shown in the Supplementary Appendix.

## **VEEV complex, EEEV and MADV rRT-PCR design**

Distinct alignments were established for the VEEV complex, EEEV, and MADV using comprehensive genome sequences from the NCBI GenBank (22) and aligned with MegAlign software (DNASTAR, Madison, WI). The VEEV complex alignment encompassed complete genomes from Cabassou, Everglades, Mosso das Pedras, Mucambo, Pixuna, Rio Negro, Tonate, and VEEV subtypes (IAB, IC, ID, and IE). This compilation occurred in 2016 (n=121 sequences), with a similar one for MADV in 2019 (n=32). Employing Primer3 software (primer3.ut.ee), primers and probes were designed to contain  $\leq 1$  degenerate base and to align  $\geq 95\%$  with available sequences for each virus (Table 1). In Silico validation details can be found in Supplementary material.

## **rRT-PCR assay performance and optimization**

Primer and probe sets were evaluated in singleplex reactions containing 200 nM of each oligonucleotide and genomic RNA or quantified ssDNA containing the target region. Primer/probe sets were selected to generate the most sensitive detection based on cycle threshold (Ct) values, with preserved specificity. Primer and probe concentrations in the final reaction were then adjusted between 100 nM and 400 nM to optimize assay sensitivity. For VEEV a total

of four primers are mixed in a single reaction (Table 1). Additional validation, conditions and lower limit of detection (LLOD) in Supplementary materials.

#### **Protocol validation with acute human samples**

Acute human samples used in the protocol validation were collected in communities of Darien, the eastern most province in Panama, during three alphavirus outbreaks in 2015 and 2017. Cases identified in 2015 and 2017 were detected in the communities of Metetí, Cemaco, Tucutí, Yaviza, Nicanor, La Palma and El Real de Santa María (Figure 1A). The Darien province borders Colombia and encompasses the Darien Gap, and the Darien National Park, a UNESCO-designated World Heritage Site (23).

#### **Patient recruitment in 2015 and 2017**

Febrile patients were identified during an enhanced surveillance program by our outbreak response team using house-by-house visits during the 2015 and 2017 outbreaks. Blood samples were drawn from patients that met the case definition during the outbreak investigation.

#### **Prospective acute disease surveillance in 2021 and 2022**

In 2021, surveillance for emerging pathogens was established in Panama as part of the USA-National Institute of Allergy and Infectious Diseases (NIAID), Centers for Research in Emerging Infectious Diseases Network initiative. The Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO) in Panama undertakes acute febrile surveillance across ten Health Centers in Panama and Darien Provinces (Figure 1 B)



(<https://www.utmb.edu/createneo/home/create-neo-home>). Additional information of inclusion criteria are provided in supplementary materials.

#### **Laboratory testing for acute disease surveillance**

Acute samples (0-5 days) were first screened against DENV, CHIKV and ZIKV virus using rRT-PCR as described previously (24), followed by testing with the newly designed MADV/VEEV rRT-PCR.

#### **Mosquito collection**

Mosquitoes were collected in a forested area (100 x 100 meters) in El Real de Santa María during the 2015 outbreak response. CDC light traps were employed over a 12-hour period (6:00 pm to 6:00 am), positioned 1.5 meters above ground level. These traps, equipped with octanol and CO<sub>2</sub> as bait, were utilized for the encephalitis vector survey. Captured mosquitoes were anesthetized, identified to species using taxonomic keys (25), and preserved in liquid nitrogen. Specimens were grouped by species, with a maximum of 20 individuals per pool for subsequent analyses.

#### **Viral isolation from mosquito pools**

Mosquito pool homogenates were prepared with 20 – 50 mosquitoes in 2 mL of minimum essential medium supplemented with penicillin and streptomycin, and 20% fetal bovine serum, homogenized using a Tissue Lyser (Qiagen, Hidden, Germany) and centrifuged at 12000 rpm for 10 mins. A total of 200 µL of serum or mosquito homogenate was inoculated in each of two 12.5-cm<sup>2</sup> flasks of Vero cells (*Cercopithecus aethiops* kidney normal cells, ATCC® CCL-81™)

. Vero cells were supplemented with 10% fetal bovine serum (FBS) for growth and maintained with 2% (FBS) and 1% penicillin/streptomycin at 37°C. Samples were passed twice and monitored for cytopathic effect (CPE). All viral isolations were undertaken under in the biosafety level-3 (BSL-3) containment laboratory at the Gorgas Memorial Institute in Panama City.

### **Generic alphavirus RT-PCR for human and mosquito samples**

Viral RNA was extracted from human sera and mosquito pool homogenates using QIAamp RNA viral extraction kit (Qiagen, Valencia, CA). Viral RNA from mosquitoes was also extracted using the Macherey-Nagel extraction kit (Düren, Germany). Volume for extraction was 160 and 200 µL for human sera and mosquito pool homogenates, whereas elution volume was 60 and 50 µL respectively. Sera and mosquito homogenates were tested in 25 µL reactions for alphaviruses using a universal alphavirus RT-PCR, as previously described (19). Antibody response was assessed in all human sera samples from 2015 as described previously (26), further details are provided in supplementary material.

### **Viral metagenomic sequencing**

To confirm virus species, subtype, and genotype, we sequenced seven selected VEEV complex rRT-PCR positive mosquito and human samples from 2015 and 2022 using SMART-9N metagenomic sequencing as previously describe (27). Additional information is provided in supplementary material.

## **VEEV Phylogenetic analysis**

All available VEEV genome sequences, in GenBank, representing all antigenic complex were selected to construct the alignment, duplicated sequences, partial sequences and overlapping sequences were removed. Finally, the novel complete or near complete VEEV genome sequences (n=7) were aligned with 132 representative VEEV genomes retrieved from NCBI GenBank using MAFFT version 7 (28). Selection of the best-fitting nucleotide substitution model and maximum likelihood phylogenetic reconstruction were performed with IQ-Tree v2.2.0.3(29). Statistical robustness of the tree topology was assessed with 1,000 ultrafast bootstrap replicates.

## **Results**

### **rRT-PCR analytical evaluation**

Primers and probes for the VEE complex singleplex and MADV/EEEV duplex rRT-PCRs are shown in Table 1 along with the optimized final reaction concentrations. The dynamic range for each assay extended from 2.0 to 8.0 log<sub>10</sub> copies/μL (Figures 1 and S1). For the VEEV complex assay, the linear range was evaluated with ssDNA for subtypes IAB and IV and RNA from subtype IC (2.0 to 5.0 log<sub>10</sub> copies/μL; Figure 1). The 95% LLODs, expressed in copies/μL, were: VEEV subtype IAB, 120; VEE subtype IV, 110; MADV, 19; EEEV, 19. Assay exclusivity was evaluated by testing genomic RNA from VEEV subtype IC, EEEV, and a set of arboviruses, including flavi-, bunya-, and alphaviruses on a single run of the VEEV complex and MADV/EEEV rRT-PCRs. VEEV complex and EEEV only yielded signals in the respective assays for these viruses. None of the other tested viruses generated a signal in either assay. In

addition, none of the 56 serum samples from Georgia, USA, or Asunción, Paraguay, tested positive in either assay.

### **Validation with clinical samples**

A total of 15 febrile patients from 2015 and 2017 alphavirus outbreaks that met the suspected or probable case definition were used to validate the new molecular assays. Previously, a total of eleven (11/15) acute sera samples collected during the in 2015 and 2017 alphavirus outbreaks had tested positive using a generic alphavirus RT-PCR and were confirmed later by sequencing as VEEV-ID infections (17). In 2021, a second round of generic alphavirus RT-PCR using the same set of primers was run on these 15 stored samples, and all of them tested negative. Notably, using the newly designed rRT-PCR, we were able to detect 10 VEEV complex RNA positive samples (Ct range: 27 – 38), including two samples that had tested negative at the initial screening in 2017 (Table 2). Three of the VEEV complex rRT-PCR-positive samples were also anti-VEEV IgG and IgM positive, with only 0, 2, and 3 days since the onset of symptoms, respectively (Table 2). One sample was rRT-PCR positive for both VEEV and MADV viruses.

### **Prospective disease surveillance**

A total of 118 febrile patients were recruited from November 16, 2021, to December 1, 2022. Of these 84 (71.2%) were acute patients with onset of symptoms ranging from 0-5 days. A total of 42 patients (50.0 %) were DENV1 positive. We detected VEEV RNA (Ct range: 15-20) in five patients (11.9%; 95% CI: 4.0 – 25.6) with suspected dengue infection, one of which was from a fatal case in 2022. Details and results of disease surveillance are presented in Figure 3.

## **Viral detection in mosquito pools**

A total of 1307 mosquitoes belonging to 35 species and 12 genera were collected in the community of El Real de Santa Maria, Panama, during a period of five days in 2015 (table 3). The most abundant mosquito species was *Coquilletidia venezualensis* (37.5%, n=490 of 1307) and *Culex Melanoconion vomerifer* (34.4%, n=450 of 1307). Mosquito species, number of individuals, and pools are shown in Table 3. Of 150 mosquito pools, 3 *Cx. (Mel.) vomerifer* mosquito pools tested positive for VEEV by rRT-PCR (Ct range:26-30). Two of these rRT-PCR-positive pools also yielded viral isolates.

## **VEEV Subtype identification**

Three mosquito pools and 4 human samples (including one from a fatal case in 2022), that tested positive with the new VEEV complex rRT-PCR were sequenced using a virus untargeted approach (27). Twenty-fold genome coverage per base pair ranged from 45% to 100% (Table 4). Percentage of genome identity with VEEV reference strain ranged from 87.7% to 90.0% (Table 4), while identity with the Panamanian VEEV ID subtype prototype strain 3880 ranged from 96 to 97% (Table 4). Maximum likelihood phylogenetic analysis indicated that the new viral genomes cluster together with historical Panamanian VEEV ID subtype strains within the Panama/Peru genotype (bootstrap statistical support =100; Figure 4).

## **Discussion**

Encephalitic alphaviruses have been detected throughout the Americas and may account for a significant proportion of non-dengue acute febrile illness (1, 2, 5, 9). Assays for their molecular detection, although existing (14–20), are often time-consuming, involving multiple PCR rounds

or subsequent genome sequencing limited to well-equipped facilities (14–20). Co-circulation and the potential for co-infection with these viruses further complicate their identification, especially when clinical presentations are similar, and convenient methods for detecting VEEV complex and MADV are lacking (19). In Panama, for instance, both VEEV subtype ID and MADV have been identified, with co-circulation detected along the Colombian border (5–7). Typically, cases are identified during the neurological phase of the disease (5, 30), where the virus is cleared from serum, necessitating reliance on serological testing. Given that alphaviruses can induce IgM responses lasting 2 to 3 months, anti-VEEV or anti-MADV IgM detection alone could lead to misdiagnosis without seroconversion(5, 30).

We have developed a singleplex and duplex rRT-PCRs for detecting VEEV complex, MADV, and EEEV viral RNA in clinical and mosquito samples. These assays identified VEEV ID subtype and MADV in samples previously negative using a reference RT-PCR (19). We also identified a VEEV ID subtype - MADV co-infection, highlighting an advantage of our VEEV complex and MADV/EEEV rRT-PCRs over prior methods. Co-infection cases are epidemiologically significant and may have clinical relevance if associated with more severe disease (5). Our rRT-PCR assays can be rapidly integrated into testing algorithms in endemic regions. The current rRT-PCR detects VEEV ID subtype RNA within the initial 5 days of symptoms, preceding IgM and IgG antibody responses which usually manifest after 5–7 days following symptom onset (31). Intriguingly, three patients with detectable VEEV complex RNA were also VEEV IgM and IgG-reactive, suggesting possible VEEV re-infections with potential implications for vaccine development. However, early IgM responses cannot be ruled out, necessitating further research on alphavirus humoral immunity.

317 Through our prospective disease surveillance in Panama, we have demonstrated a notable  
318 prevalence of alphavirus detection. About 11.9% of individuals exhibiting symptoms similar to  
319 dengue have been found to have VEEV infections. These findings align with earlier assessments  
320 indicating that roughly 10% of clinical dengue cases in endemic countries can be attributed to  
321 VEEV infection (2). Moreover, this suggest a co-circulation of alphaviruses alongside other  
322 endemic arboviral infections, including dengue. Given the clinical similarities between VEEV  
323 complex infections and dengue, there exists the potential for underestimating the true burden of  
324 VEEV-related disease (2).

325 VEEV ID subtype RNA was found in *Cx. (Mel.) vomerifer* mosquito pools trapped during the  
326 2015 outbreak in El Real de Santamaria . These mosquitoes were previously implicated as  
327 VEEV ID subtype vectors (2). Two pools yielded viral isolates. Notably, pan-alphavirus  
328 conventional RT-PCRs failed to detect viral RNA in these pools, suggesting the newly rRT-  
329 PCR's heightened sensitivity for VEEV complex RNA detection in mosquitoes. Neither MADV  
330 nor EEEV infections were detected in mosquitoes using various methods. A similar pattern  
331 emerged from past outbreak investigations by our group in Panama (26, 32). Interestingly,  
332 MADV detection frequency in *Culex (Mel.)* spp. mosquitos are low in Panama (33, 34), unlike  
333 the endemic region of Iquitos, Peru, where MADV in the enzootic vector *Culex (Mel.) pedroi* is  
334 frequent (9, 35). Reasons for this variation in MADV and VEEV ID subtype frequency in  
335 Panama and MADV and VEEV in Panama vs Iquitos remain uncertain, possibly involving  
336 vector competence or viral competition, even enhanced VEEV ID subtype transmission via  
337 insect-specific viruses (36).

While our assays were validated with a limited number of human and mosquito samples, prospective surveillance allowed further validation. Unlike previous methods relying on plasmids, viral isolates, or a few human sera samples (13–21), we validated with human sera, mosquitoes, and post-mortem tissue samples. Our approach failed to detect two samples previously positive using standard alphavirus generic primers (19). Interestingly, a subsequent generic alphavirus RT-PCR in 2017 also failed to reamplify the former positives, possibly due to viral RNA degradation over time (37)

An rRT-PCR based on 33 VEEV sequences was reported by Vina-Rodriguez et al. but excluded other VEEV complex species and lacked clinical evaluation (21). Our assays used more complete genome sequences, with in silico primer and probe alignment to contemporary sequences. Untargeted metagenomic sequencing confirmed VEEV ID subtype detection using VEEV complex primers; this subtype has been detected in central and eastern Panama regions (7). These findings highlight molecular and genomic approaches potential to enhance detection of acute encephalitis alphavirus infections, even in archived samples .

Further prospective testing is necessary for comprehensive clinical performance characterization, including quantitative diagnostics and challenging assays with interfering substances. Limitations include the design requiring two separate assays for three viruses due to overlapping optimal design targets. However, the two rRT-PCRs can be executed simultaneously, improving lab workflow. The VEEV complex assay can also be multiplexed with rRT-PCRs for other neurotropic arboviruses without performance loss (manuscript in preparation).



We developed sensitive and specific VEEV complex, MADV, and EEEV rRT-PCRs, surpassing available molecular methods. These assays detect VEEV-MADV co-infections, VEEV human infections, potential VEEV reinfections, and active VEEV viral circulation in mosquitoes during alphavirus outbreaks. Implementing these assays in endemic regions may enhance neurotropic alphavirus identification and characterization.

### **Acknowledgements**

We thank Xacdiel Rodriguez, Yelissa Rios, Yaneth Pittí, Oriel Lezcano and Eddier Rivera and Mileika Santos for technical support with sample processing and mosquito classification and Alberto Cumbreira for the map construction. We also thank Leyda Abrego for providing reagents for the rRT-PCR and Milena Gomez, Thais M. Coletti, Esmeria Rocha, Geovana Maria Pererira, and Erika R. Manuli for technical support with metagenomic sequencing.

### **Funding Sources**

JPC is funded by the Clarendon Scholarship from University of Oxford and Lincoln-Kingsgate Scholarship from Lincoln College, University of Oxford (grant number SFF1920\_CB2\_MPLS\_1293647). This work was supported by SENACYT, through the grants number FID-16-201 and FID-2021-96 grant to JPC; the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant K08AI110528 to JJW) and the Centers for Research in Emerging Infectious Diseases (CREID) Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO) 1U01AI151807 grant awarded to NV/KAH by the National Institutes of Health (NIH); and by the Medical Research Council-São Paulo Research Foundation CADDE partnership award (MR/S0195/1 and

FAPESP18/14389-0 to NRF) (<https://caddecentre.org>). CAD was supported by the NIHR HPRU in Emerging and Zoonotic Infections, a partnership between PHE, University of Oxford, University of Liverpool and Liverpool School of Tropical Medicine (grant no. NIHR200907).

## References

1. Navarro JC, Carrera JP, Liria J, Auguste AJ, Weaver SC., 2017. Alphaviruses in Latin America and the introduction of chikungunya virus. *Human Virology in Latin America: From Biology to Control*, Cham, Switzerland: Springer International, Publishing, 169–192.
2. Aguilar P v., Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC., 2011. Endemic Venezuelan equine encephalitis in the Americas: Hidden under the dengue umbrella. *Future Virol* 6: 721–740.
3. Arrigo NC, Adams AP, Weaver SC., 2010. Evolutionary Patterns of Eastern Equine Encephalitis Virus in North versus South America Suggest Ecological Differences and Taxonomic Revision. *J Virol*; 84:1014–25.
4. Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, Vallejo E, Madrid C, Aguayo N, Gotuzzo E, Suarez V, Morales AM, Beingolea L, Reyes N, Perez J, Negrete M, Rocha C, Morrison AC, Russell KL, Blair PJ, Olson JG, Kochel TJ. 2010. Arboviral etiologies of acute febrile illnesses in western south America, 2000-2007. *PLoS Negl Trop Dis*. 10;4(8):e787. doi: 10.1371/journal.pntd.0000787.
5. Carrera J-P, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, Abadía I, Castaño E, Sosa N, Báez C, Estripeaut D, Díaz Y, Beltrán D, Cisneros J, Cedeño HG, Travassos da Rosa AP, Hernandez H, Martínez-Torres AO, Tesh RB, Weaver SC. 2013. Eastern Equine Encephalitis in Latin America. *New Eng J Med* 2013; 369:732–44.
6. Carrera JP, Pittí Y, Molaes-Martínez JC, Casal E, Pereyra-Elias R, Saenz L, Guerrero I, Galué J, Rodriguez-Alvarez F, Jackman C, Pascale JM, Armien B, Weaver SC, Donnelly CA, Vittor AY. 2020. Clinical and serological findings of madariaga and venezuelan equine encephalitis viral infections: A follow-up study 5 years after an outbreak in Panama. *Open Forum Infect Dis*;7(9): ofaa359, <https://doi.org/10.1093/ofid/ofaa359>.
7. Quiroz E, Aguilar P v., Cisneros J, Tesh RB, Weaver SC. 2009. Venezuelan equine encephalitis in Panama: Fatal endemic disease and genetic diversity of etiologic viral strains. *LoS Negl Trop Dis*. 2009 Jun 30;3(6):e472. doi: 10.1371/journal.pntd.0000472.
8. Corniou B, Ardoin P, Bartholomew C, Ince W, Massiah V. 1972. First isolation of a South American strain of Eastern Equine virus from a case of encephalitis in Trinidad. *Trop Geogr Med*;24:162-7.
9. Aguilar P v., Robich RM, Turell MJ, O’Guinn ML, Klein TA, Huaman A, Guevara C, Rios Z, Tesh RB, Watts DM, Olson J, Weaver SC. 2007. Endemic eastern equine encephalitis in the Amazon region of Peru. *Am J Trop Med Hyg* 76:293-8.
10. Vittor AY, Armien B, Gonzalez P, Carrera J-P, Dominguez C, Valderrama A, Glass GE, Beltran D, Cisneros J, Wang E, Castillo A, Moreno B, Weaver SC. 2016. Epidemiology of Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan Equine Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien, Panama. . *PLoS Negl Trop Dis*; 10(4): e0004554. doi:10.1371/journal.pntd.0004554

11. Gil LHVg, Magalhaes T, Santos BSAS, Oliveira L v., Oliveira-Filho EF, Cunha JLR, Fraiha ALS, Rocha BMM, Longo BC, Ecco R, Faria GC, Furtini R, Drumond SRM, Maranhão RPA, Lobato ZIP, Guedes MIMC, Teixeira RBC, Costa EA. 2021. Active circulation of madariaga virus, a member of the eastern equine encephalitis virus complex, in northeast brazil. *Pathogens*. 3;10(8):983. doi: 10.3390/pathogens10080983.
12. Lednicky JA, White SK, Mavian CN, el Badry MA, Telisma T, Salemi M, OKech BA, Beau De Rochars VM, Morris JG. 2019. Emergence of Madariaga virus as a cause of acute febrile illness in children, Haiti, 2015-2016. *PLoS Negl Trop Dis*. 10;13(1):e0006972. doi: 10.1371/journal.pntd.0006972
13. Pfeffer M, Proebster B, Kinney RM, Kaaden OR. 1997. Genus-specific detection of alphaviruses by a semi-nested reverse transcription-polymerase chain reaction. *m J Trop Med Hyg* ;57(6):709-18. doi: 10.4269/ajtmh.1997.57.709
14. Brightwell G, Brown JM, Coates DM. 1998. Genetic targets for the detection and identification of Venezuelan equine encephalitis viruses. *Arch Virol*;143(4):731-42. doi: 10.1007/s007050050326..
15. Romeiro MF, de Souza WM, Tolardo AL, Vieira LC, Henriques DA, de Araujo J, Siqueira CEH, Colombo TE, Aquino VH, da Fonseca BAL, de Moraes Bronzoni RV, Nogueira ML, Durigon EL, Figueiredo LTM. 2016. A real-time RT-PCR for rapid detection and quantification of mosquito-borne alphaviruses. *Arch Virol*;161(11):3171-7. doi: 10.1007/s00705-016-3019-0.
16. Linssen B, Kinney RM, Aguilar P, Russell KL, Watts DM, Kaaden OR, Pfeffer M. 2000. Development of reverse transcription-PCR assays specific for detection of equine encephalitis viruses. *J Clin Microbiol*;38(4):1527-35. doi: 10.1128/JCM.38.4.1527-1535.2000
17. Wang E, Paessler S, Aguilar P v., Carrara AS, Ni K, Greene IP, Weaver SC. 2006. Reverse transcription-PCR-enzyme-linked immunosorbent assay for rapid detection and differentiation of alphavirus infections. *J Clin Microbiol*;44(11):4000-8. doi: 10.1128/JCM.00175-06.
18. Pisano MB, Seco MPS, Ré VE, Fariás AA, Contigiani MS, Tenorio A. 2012. Specific detection of all members of the Venezuelan Equine Encephalitis complex: Development of a RT-Nested PCR. *J Virol Methods*;186(1-2):203-6. doi: 10.1016/j.jviromet.2012.05.009.
19. Sánchez-Seco MP, Rosario D, Quiroz E, Guzmán G, Tenorio A. 2001. A generic nested-RT-PCR followed by sequencing for detection and identification of members of the alphavirus genus. *J Virol Methods*;95(1-2):153-61. doi: 10.1016/s0166-0934(01)00306-8.
20. Bronzoni RVM, Moreli ML, Cruz ACR, Figueiredo LTM. 2004. Multiplex nested PCR for Brazilian Alphavirus diagnosis. *Trans R Soc Trop Med Hyg*;98(8):456-61. doi: 10.1016/j.trstmh.
21. Vina-Rodriguez A, Eiden M, Keller M, Hinrichs W, Groschup MH. 2016. A quantitative real-time RT-PCR assay for the detection of venezuelan equine encephalitis virus utilizing a universal alphavirus control RNA. *Biomed Res Int*;2016:8543204. doi: 10.1155/2016/8543204.
22. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Ostell J, Pruitt KD, Sayers EW. 2018. GenBank. *Nucleic Acids Res* <https://doi.org/10.1093/nar/gkx1094>.
23. Darien National Park. <https://whc.unesco.org/en/list/159/>. Accessed August 31, 2023.

24. Santiago GA, Vázquez J, Courtney S, Matías KY, Andersen LE, Colón C, Butler AE, Roulo R, Bowzard J, Villanueva JM, Muñoz-Jordan JL. 2018. Performance of the Trioplex real-time RT-PCR assay for detection of Zika, dengue, and chikungunya viruses. *Nat Commun.* 2018 Apr 11;9(1):1391. doi: 10.1038/s41467-018-03772-1.
25. Sallum MAM, Forattini OP. 1996. Revision of the spissipes section of culex (melanoconion) (diptera: Culicidae). *J Am Mosq Control Assoc*;12(3 Pt 2):517-600.
26. Carrera J-P, Cucunuba ZM, Neira K, Lambert B, Pitti Y, Liscano J, Garzon JL, Beltran D, Collado-Mariscal L, Saenz L, Sosa NNN, Rodriguez-Guzman LD, Gonzalez P, Lezcano AG, Pereyra-Elias R, Valderrama A, Weaver SC, Vittor AY, Armien B, Pascale JM, Donnelly CA. 2020. Endemic and epidemic human alphavirus infections in eastern Panama: An analysis of population-based cross-sectional surveys. *Am J Trop Med Hyg*, 103(6), 2429–2437
27. Claro IM, Ramundo MS, Coletti TM, da Silva CAM, Valenca IN, Candido DS, Sales FCS, Manuli ER, de Jesus JG, de Paula A, Felix AC, Andrade P dos S, Pinho MC, Souza WM, Amorim MR, Proenca-Modena JL, Kallas EG, Levi JE, Faria NR, Sabino EC, Loman NJ, Quick J. 2023. Rapid viral metagenomics using SMART-9N amplification and nanopore sequencing. *Wellcome Open Res*;6:241. doi: 10.12688/wellcomeopenres.17170.2..
28. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. *Mol Biol Evol.* 2013 Apr;30(4):772-80. doi: 10.1093/molbev/mst010.
29. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, Lanfear R, Teeling E. 2020. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol Biol Evol.* 2020 May 1;37(5):1530-1534. doi: 10.1093/molbev/msaa015.
30. Luciani K, Abadía I, Martínez-Torres AO, Cisneros J, Guerra I, García M, Estripeaut D, Carrera JP. 2015. Case report: Madariaga virus infection associated with a case of acute disseminated encephalomyelitis. *Am J Trop Med Hyg*;92(6):1130-2. doi: 10.4269/ajtmh.14-0845.
31. Torres-ruesta A, Chee RSL, Ng LFP. 2021. Insights into antibody-mediated alphavirus immunity and vaccine development landscape. *Microorganisms*;9(5):899. doi: 10.3390/microorganisms9050899.
32. Torres R, Samudio R, Carrera JP, Young J, Maârquez R, Hurtado L, Weaver S, Chaves LF, Tesh R, Caâceres L. 2017. Enzootic mosquito vector species at equine encephalitis transmission foci in the República de Panama. *PLoS One*;12(9):e0185491. doi: 10.1371/journal.pone.0185491.
33. Dietz WH, Galindo P, Johnson KM. 1980. Eastern equine encephalomyelitis in Panama: The epidemiology of the 1973 epizootic. *Am J Trop Med Hyg.* 29(1):133-40. doi: 10.4269/ajtmh.1980.29.133.
34. Srihongse S, Galindo P. 1967. The isolation of eastern equine encephalitis virus from Culex (Melanoconion) taeniopus Dyar and Knab in Panama. *Mosquito News* 27:74–76.
35. Turell MJ, O'Guinn ML, Jones JW, Sardelis MR, Dohm DJ, Watts DM, Fernandez R, Travassos Da Rosa A, Guzman H, Tesh R, Rossi CA, Ludwig G v., Mangiafico JA, Kondig J, Wasieloski LP, Pecor J, Zyzak M, Schoeler G, Mores CN, Calampa C, Lee JS,

- Klein TA, 2006. Isolation of Viruses from Mosquitoes (Diptera: Culicidae) Collected in the Amazon Basin Region of Peru. *J Med Entomol* 42:891–898.
36. Olmo RP, Tadjro YMH, Aguiar ERGR, de Almeida JPP, Ferreira F v., Armache JN, de Faria IJS, Ferreira AGA, Amadou SCG, Silva ATS, de Souza KPR, Vilela APP, Babarit A, Tan CH, Diallo M, Gaye A, Paupy C, Obame-Nkoghe J, Visser TM, Koenraadt CJM, Wongsokarijo MA, Cruz ALC, Prieto MT, Parra MCP, Nogueira ML, Avelino-Silva V, Mota RN, Borges MAZ, Drumond BP, Kroon EG, Recker M, Sedda L, Marois E, Imler JL, Marques JT. 2023. Mosquito vector competence for dengue is modulated by insect-specific viruses. *Nat Microbiol* 8:135–149.
37. Relova D, Rios L, Acevedo AM, Coronado L, Perera CL, Pérez LJ. 2018. Impact of RNA degradation on viral diagnosis: An understated but essential step for the successful establishment of a diagnosis network. *Vet Sci*;5(1):19. doi: 10.3390/vetsci5010019.

## Tables

**Table 1.** Primers and probes in the VEEV and MADV/EEEV rRT-PCRs.

Name	Sequence <sup>a</sup>	Concentration (nM) <sup>b</sup>	Location (5'-3') <sup>c</sup>	Sequences Fully Matching <sup>d</sup>
<i>VEEV</i>				
VEEV Forward 1	GAAAGTTCACGTT	200	44-67	156/159 (98)
	GAYATCGAGGA			
VEEV Forward 2	GAAGGTTACGTT	200	144-163	159/159 (100)
	GAYATCGAGGA			
VEEV Reverse 1	GCTCTGGCRTTAG	200	112-134	158/159 (99)
	CATGGTC			
VEEV Reverse 2	GCTCTAGCRTTAG	200	112-134	158/159 (99)
	CATGGTC			
VEEV Probe	5'-FAM-	400	112-134	158/159 (99)
	TTGAGGTAGAAGC			
	HAAGCAGGTC-			
	BHQ-1-3'			
<i>MADV/EEEV</i>				

ME Forward	GAGATAGAAGCM	400	121-141; 99-119	31/32 (97); 1/449
	ACGCAGGTC			(100)
ME Reverse	TGYTTGGAATGCG	400	255-272; 233-250	32/32 (100); 9/449
	TGTGC			(98)
	5'-FAM-			31/32 (97)
MADV Probe	CATCGAAAGCGAA	200	195-214	
	GTGGACC-BHQ-1-			
	3'			
	5'-CFO560-			6/449 (99)
EEEV Probe	TGAGGGAGAAGT	400	176-198	
	GGAYACAGACC-			
	BHQ-1-3'			

Abbreviations: BHQ, black hole quencher; CFO560, CAL Fluor Orange 560; FAM, Fluorescein

<sup>a</sup> probe sequences listed 5'-fluorophore-sequence-quencher-3'

<sup>b</sup> Concentration in the final reaction mixture

<sup>c</sup> Location in the following complete genome sequences: VEEV strain VEEV/Homo sapiens/GTM/69Z1/1969/IAB (Accession number KC344505.2); MADV strain Homo sapiens/Haiti-1901/2016 (MH359233.1); EEEV strain EEEV/Culiseta melanura/USA/SL13-0764-C/2013 (Accession number KX029319.1)

<sup>d</sup> Displayed as number of complete genome sequences without a mismatch in the primer/probe sequence over all complete genome sequences aligned (%). Genomes downloaded 22 Sept 2021. Data shown for the combination of forward and reverse VEEV primers.

**Table 2. Characteristics and laboratory results of samples used for protocol validation patients and clinical samples and laboratory results.** Acute samples selected from the 2015 and 2017 alphavirus outbreaks in Darien Province.

Code	Township	Age*	Sex	Symptoms onset	Days of symptoms	RT-PCR-Alpha (2015)	RT-PCR-Alpha (2021)	rRT-PCR-VEE	Ct values	IgM-VEEV	IgM-MADV	IgG-VEEV	IgG-MADV	PRNT-VEEV φ	PRNT-MADV φ
258384	El Real	0-9	M	Aug. 2015	0	pos	neg	pos	29.3	neg	neg	neg	neg	<1:20	<1:20
267738	Cemaco	0-9	M	July 2017	3	neg	neg	pos	37.8	pos	neg	neg	neg	<1:20	<1:20
267411	Tucuti	0-9	F	July 2017	5	neg	neg	neg	-	pos	neg	pos	pos	1:40	1:40
258380	El Real	0-9	F	Aug. 2015	1	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
267410	Yaviza	0-9	F	July 2017	2	neg	neg	neg	-	pos	neg	pos	neg	<1:20	<1:20
258657	Yaviza	10-19	M	Sept. 2015	0	pos	neg	pos	28	neg	neg	neg	neg	<1:20	<1:20
258535	Nicanor	20-29	F	Sept. 2015	2	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
258401	La Palma	20-29	M	Aug. 2015	2	pos	neg	pos	29	neg	neg	neg	neg	<1:20	<1:20
258395	Metetí	30-39	M	Aug. 2015	2	neg	neg	pos	37	pos	neg	neg	neg	<1:20	<1:20
258399	El Real	30-39	M	Aug. 2015	1	pos	neg	pos	26	neg	neg	neg	neg	<1:20	<1:20
258385	El Real	30-39	M	Aug. 2015	2	pos	neg	pos	37	neg	neg	neg	neg	<1:20	<1:20
258398	El Real	30-39	M	Aug. 2015	0	pos	neg	pos	27	neg	neg	pos	neg	<1:20	<1:20
258536	Metetí	30-39	F	Sept. 2015	2	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
258386	El Real	30-39	M	Aug. 2015	5	pos	neg	pos	34	neg	neg	neg	neg	ND	ND
258379	El Real	≥ 40	F	Aug. 2015	2	pos	neg	pos	31	neg	neg	neg	neg	<1:20	<1:20

\*Age categories in years

φ Base on PRNT-80

Abbreviations: Ct, cycle threshold; neg, negative; pos, positive, ND=not done.



**Table 3. Mosquito species collected during the 2015 outbreak in El Real de Santa Maria, Panama.**

Mosquitos species	N	(%)	# Pools	VEE-rRT-PCR Positive	MADV-rRT-PCR Positive	Viral solates
<i>Coquillettidia venezuelensis</i>	490	37.5	29	0	0	0
<i>Culex</i> (Melanoconion) <i>) vomerifer</i>	450	34.4	27	3	0	2
<i>Culex</i> (Melanoconion) <i>) pedroi</i>	32	2.4	4	0	0	0
<i>Aedes serratus</i>	31	2.4	7	0	0	0
<i>Aedes</i> sp.	30	2.3	5	0	0	0
<i>Culex</i> (Melanoconion) <i>) sp.</i>	30	2.3	6	0	0	0
<i>Culex</i> ( <i>Culex</i> ) <i>interrogator</i>	27	2.1	5	0	0	0
<i>Anopheles trianulatus</i>	23	1.8	2	0	0	0
<i>Aedes eupoclamus</i>	14	1.1	4	0	0	0
<i>Culex</i> ( <i>Culex</i> ) <i>nigripalpus</i>	14	1.1	3	0	0	0
<i>Culex</i> ( <i>Culex</i> ) sp.	14	1.0	4	0	0	0
<i>Culex</i> (Melanoconion) <i>) atratus</i>	14	1.0	1	0	0	0
<i>Culex</i> (Melanoconion) <i>) adamesi</i>	13	1.0	3	0	0	0
Others*	125	9.6	50	0	0	0
Total	1307	100	150	3	0	2

Species <1% abundance are listed as Others.

# Numbers of mosquito pools

**Table 4. Metadata and sequencing statistics for selected VEEV complex RNA positive samples.**

ID	Collection year	Location	Host species	%genome coverage 20X	% Nt Identity with genome reference <sup>a</sup>	% Identity with strain 3880 <sup>b</sup>	C values
700677	2015	Darien	<i>Culex (Mel.) vomerifer</i>	100	89.8	92.1	27
700680	2015	Darien	<i>Culex (Mel.) vomerifer</i>	100	89.8	92.2	31
700732	2015	Darien	<i>Culex (Mel.) vomerifer</i>	100	90	92.3	26
258379	2015	Darien	<i>Human</i>	99.9	89.6	92	31
258398	2015	Darien	<i>Human</i>	70	88.7	90.7	27
258401	2015	Darien	<i>Human</i>	90.6	87.7	90	29
278716	2022	Darien	<i>Human</i>	45.98	88.1	90	20

<sup>a</sup>Genbank accession no. NC\_001449.1

<sup>b</sup>Panamanian VEEV ID subtype prototype strain 3880, GenBank accession no. L00930.1

Nt=Nucleotide.

## Figure legends

**Figure 1. Map with the distribution of VEEV human cases in Darien province in 2015 and 2017 and Health centres in Panama and Darien Provinces.** A. Distribution of VEEV cases used for protocol validation. Red dots represent the number of cases reported by locality. B. Distribution of Health centers used for prospective febrile surveillance in Panama and Darien provinces. Map was created with ArcGIS Desktop 10.6 using shapefiles from Esri. Data sources for the shapefiles include Esri, Garmin International Inc., US Central Intelligence Agency, and National Geographic Society (39).

**Figure 2. VEE amplification curves across a range of concentrations.** Amplification curves are shown across a range of concentrations for the VEE complex rRT-PCR with ssDNA (gray curves, subtype IAB) and RNA (pink dotted curves, subtype IC). ssDNA was tested in

quaduplicate at 8.0, 6.0, 4.0, 2.0 and 1.0 log<sub>10</sub> copies/μL (labelled a-e, respectively). 10-fold dilutions of VEEV subtype IC RNA were tested in duplicate starting at the highest concentration available (5.0 log<sub>10</sub> copies/μL).

**Figure 3. Flowchart of patient recruitment, characteristics and RT-PCR results of febrile patients detected throughout disease surveillance.** Febrile patients were recruited from November 16, 2021, to December 1, 2022, in ten health care centers of Panama and Darien provinces.

**Figure 4. VEEV complex maximum likelihood phylogenetic tree.** Maximum likelihood phylogenetic was estimated using 139 complete or near complete VEEV genomes. Publicly available Panamanian VEEV ID subtype strains are highlighted in grey (n=) and genomes generated in this study (n=7) are highlighted in red. Bootstrap statistical support are shown for selected nodes. NCBI GenBank accessions numbers for the new VEEV genomes are: XX-XX.

Supplementary materials for:

**Real-time RT-PCR for Venezuelan equine encephalitis complex, Madariaga and Eastern equine encephalitis viruses: application in human and mosquito public health surveillance**

**rRT-PCR in silico validation**

In silico primer/probe specificity was checked by aligning sequences in BLAST (blast.ncbi.nlm.nih.gov) against (i) all available sequences and (ii) only alphavirus sequences while excluding the VEEV complex or MADV, respectively. Due to the similarity between MADV primers and EEEV sequences, all available EEEV complete genome sequences (n=441) were aligned and separate MADV and EEEV probes were designed for an rRT-PCR duplex assay. Alignments for each virus were repeated with all sequences available in September 2021 to confirm primer and probe sequences in contemporary strains.

**rRT-PCR optimization**

Primers were obtained from Integrated DNA Technologies (IDT, Coralville, Iowa); probes were obtained from Biosearch Technologies (Hoddesdon, United Kingdom). VEEV subtype IC and EEEV genomic RNAs were purchased from Vircell Microbiologists (Granada, Spain). Quantified Ultramer ssDNA containing the assay target region was obtained for all viruses (IDT, Coralville, Iowa) to evaluate assay performance. For ssDNA synthesis, target region sequences were selected from specific strains of VEE subtype IAB (Accession number KC344505.2) and subtype IV (Pixuna virus, Accession number

NC\_038673.1), MADV (Accession numbers MH359233.1 and KJ469626.1), and EEEV (Accession number KX029319.1).

### **rRT-PCR reaction and cycling conditions**

rRT-PCRs were performed in 25 µL reactions using the SuperScript III Platinum One-Step Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5 µL of the nucleic acid template. The analytical evaluation was performed on a Rotor-Gene Q instrument (Qiagen, Germantown, MD), and the validation with serum and mosquito pool samples was performed on an ABI7500 (Thermo Fisher). Cycling conditions were consistent with previous laboratory protocols: 52 °C × 15 min, 94 °C × 2 min, and 45 cycles of 94 °C × 15 s, 55 °C × 40 s (acquired in all channels), and 68 °C × 20 s (1–3). rRT-PCR thresholds were set based on testing with the final reaction mixtures, as described previously (1, 3). The dynamic range of each assay was determined by testing synthesized targets from each reference strain in quadruplicate at 8.0, 6.0, 4.0, 2.0, and 1.0 log<sub>10</sub> copies/µL. For the VEEV complex, the lower limit 95% detection (95% LLOD) was estimated by testing 10 replicates of 2-fold serial dilutions from 200 to 25 copies/µl. For MADV and EEEV, 95% LLOD was estimated from results of replicate testing in the dynamic range study. Probit analyses were performed using MedCalc, v20.013 (MedCalc Software, Belgium) to estimate LLOD as previously described(1, 3).

### **rRT-PCR Assay Specificity**

Specificity was evaluated by testing 56 serum samples from locations without known transmission of VEEV or MADV. These included 8 samples collected from patients in

Georgia, USA, without known travel history, and 48 samples from individuals with an acute febrile illness in Asunción, Paraguay. The latter samples have been described in detail elsewhere (2). Total nucleic acids were extracted from 200µL of serum on an EMAG instrument (BioMérieux, Durham, NC), eluted in 50 µL and tested with the VEEV complex and MADV/EEEV rRT-PCRs.

#### **rRT-PCR Assay exclusivity**

Assay exclusivity was evaluated by testing genomic RNA from the following viruses (strain in parentheses, if designated): Rift Valley fever (h85/09); Zika (ZIKV; MR766); dengue virus serotype 1 (DENV1, Hawaii 1944), DENV2 (NGC), DENV3 (Sleman/78), and DENV4 (H241); chikungunya virus (CHIKV80422); Mayaro virus (MAYV; ARV 0565, INHRR 11a-10); yellow fever virus (YFV; 17D and Asibi strains); West Nile virus (WNV; NAL); St. Louis encephalitis virus (SLEV; GML 902612, CorAn 9275); tick-borne encephalitis virus (TBEV; Japanese encephalitis virus (JEV); Semliki Forest virus (SFV); Ross River virus (RRV); Getah virus (GETV); Barmah Forest virus (BFV); and Una virus (UNAV).

#### **Outbreak case definition**

The definition of a suspected case included fever and headache, while a probable case was defined as a suspected case plus somnolence, lethargy, or convulsions. Blood samples were centrifuged in the field, and serum was stored in liquid nitrogen for transportation to the Gorgas Memorial Institute of Health Studies in Panama City.

## **Inclusion criteria for Prospective surveillance**

Cases, without malaria, human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis virus (HCV), and >5 and <75 years old, presenting with no more than 7 days with rash, and at least one of the following symptoms: fever, myalgia, arthralgia, periarticular edema, and conjunctivitis were recruited, evaluated and interviewed, to obtain clinical, and demographics characteristics and ethic consent at each health center.

## **Alphavirus serology of 2015 clinical samples**

All human serum samples were tested in duplicate for IgM antibodies to MADV and VEEV antigen using an enzyme-linked immunosorbent assay (ELISA) and confirmed by a plaque-reduction neutralization test (PRNT). For the ELISA, sucrose-acetone antigens were prepared from MADV- (prepared by Dr. Robert Shope at the Yale Arbovirus Research Unit in August 1989) and VEEV- (strain TC-83) infected mouse brain. For the PRNT, we used chimeric Sindbis virus SINV/MADV (derived from Brazilian MADV strain BeAn436087 and shown to be an accurate surrogate for MADV in these assays (4) and TC83, an attenuated vaccine strain of VEEV closely related to subtype ID strains that circulate in Panama (5). The neutralizing antibody titer was determined as the reciprocal of the highest dilution that reduced plaque count by 80% (PRNT<sub>80</sub>).


## **Metagenomic sequencing**

Viral RNA was treated to remove residual DNA with TURBO DNase (Thermo Fisher Scientific, USA) and concentrated with Zymo RNA clean & concentrator-5 (Zymo Research, USA) following the protocol instructions. cDNA synthesis and PCR was performed as described previously (6). PCR products were then purified using AMPure XP beads

(Beckman Coulter, UK) and quantified according to manufacturer's instructions with Qubit dsDNA High Sensitivity assay (Life Technologies, USA) and Qubit 3.0 instrument (Life Technologies, USA).

cDNAs were pooled using the EXP-NBD104 (1–12) and EXP-NBD114 (13–24) Native Barcoding Kits (ONT, UK). Sequencing libraries were generated using the SQK-LSK109 Kit (ONT, UK). 50 ng of the final libraries were loaded onto FLO-MIN106 flow cells on the MinION device (ONT, UK) and sequenced using MinKNOW with the standard 48-hour run script. FASTQ files were demultiplexed and trimmed using Guppy V5.0.16. (Oxford Nanopore, Oxford, United Kingdom), and then aligned and mapped to the reference genome (GenBank accession no. NC\_001449.1) using minimap2 version 2.28.0 (7) and converted to a sorted BAM file using Samtools 3 (<http://www.htslib.org>). NanoStat version 1.1.24 (<https://pypi.org/project/NanoStat/>) was used to compute the number of raw reads and minimum contig length to cover 50 percent of the genome (N50) of the aligned reads. Genome visualization was undertaken with Tablet 1.19.05.28 (8), and to compute the number of mapped reads, percentage of genome coverage, and coverage depth. Variants were detected with medaka\_variants and the consensus sequence were built using margin\_medaka\_consensus (Oxford Nanopore, Oxford), United Kingdom. Genome regions with <20x coverage were masked.





**Figure S1. Dynamic range of assays for VEE complex (A), MADV (B) and EEEV (C).** The dynamic range for each assay was established by testing ssDNA in quadruplicate at 8.0, 6.0, 4.0, 2.0 and 1.0 log<sub>10</sub> copies/μL (labelled a-e, respectively).

## References

- Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Vargas Davila MJ, Tellez Y, Sahoo MK, Balmaseda A, Harris E, Pinsky BA. 2016. Single-reaction multiplex reverse transcription PCR for detection of zika, Chikungunya, and dengue viruses. *Emerg Infect Dis*;22(7):1295-7. doi: 10.3201/eid2207.160326..
- Rojas A, Cardozo F, Cantero C, Stittleburg V, López S, Bernal C, Gimenez Acosta FE, Mendoza L, Pinsky BA, De Guillén IA, Páez M, Waggoner J. 2019. Characterization of dengue cases among patients with an acute illness, Central Department, Paraguay. *PeerJ*. 7:e7852. doi: 10.7717/peerj.7852. .
- Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, Ballesteros G, Pierro AM, Gaibani P, Guo FP, Sambri V, Balmaseda A, Karunaratne K, Harris E, Pinsky BA. 2013. Single-Reaction, Multiplex, Real-Time RT-PCR for the Detection, Quantitation, and Serotyping of Dengue Viruses. *PLoS Negl Trop Dis*;7(4):e2116. doi: 10.1371/journal.pntd.0002116.

4. Johnson BW, Kosoy O, Wang E, Delorey M, Russell B, Bowen RA, Weaver SC. 2011. Use of Sindbis/eastern equine encephalitis chimeric viruses in plaque reduction neutralization tests for arboviral disease diagnostics. *Clin Vaccine Immunol.* (9):1486-91. doi: 10.1128/CVI.05129-11.
5. Quiroz E, Aguilar P v., Cisneros J, Tesh RB, Weaver SC. 2009. Venezuelan equine encephalitis in Panama: Fatal endemic disease and genetic diversity of etiologic viral strains. *PLoS Negl Trop Dis*;3(6):e472. doi: 10.1371/journal.pntd.0000472.
6. Claro IM, Romano CM, Candido D da S, de Lima EL, Lindoso JAL, Ramundo MS, Moreira FRR, Barra LAC, Borges LMS, Medeiros LA, Tomishige MYS, Moutinho T, da Silva AJD, Rodrigues CCM, de Azevedo LCF, Villas-Boas LS, da Silva CAM, Coletti TM, Manuli ER, O'toole A, Quick J, Loman N, Rambaut A, Faria NR, Figueiredo-Mello C, Sabino EC. 2022. Shotgun metagenomic sequencing of the first case of monkeypox virus in Brazil, 2022. *Rev Inst Med Trop Sao Paulo.* 2022 Jun 24;64:e48. doi: 10.1590/S1678-9946202264048.
7. Li H. 2018. Minimap2: Pairwise alignment for nucleotide sequences. *Bioinformatics.* 2018 Sep 15;34(18):3094-3100. doi: 10.1093/bioinformatics/bty191.
8. Milne I, Stephen G, Bayer M, Cock PJA, Pritchard L, Cardle L, Shawand PD, Marshall D. 2013. Using tablet for visual exploration of second-generation sequencing data. *Brief Bioinform:* 14(2):193-202. doi: 10.1093/bib/bbs012.